United Therapeutics (NASDAQ:UTHR) CEO Sells $5,476,465.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $576.47, for a total transaction of $5,476,465.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $187,031,656.21. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $541.70 on Monday. The firm has a market cap of $23.23 billion, a price-to-earnings ratio of 19.38, a price-to-earnings-growth ratio of 2.72 and a beta of 0.49. United Therapeutics Corporation has a 52-week low of $409.07 and a 52-week high of $609.35. The company’s 50-day simple moving average is $510.30 and its 200-day simple moving average is $539.69.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the firm earned $6.41 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current year.

Institutional Trading of United Therapeutics

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of United Therapeutics during the 2nd quarter worth $2,868,735,000. Janus Henderson Group PLC increased its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Jupiter Topco LLC purchased a new position in United Therapeutics during the 2nd quarter valued at about $450,140,000. Swedbank AB raised its position in United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its position in United Therapeutics by 0.8% during the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock worth $183,306,000 after acquiring an additional 2,383 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on UTHR shares. The Goldman Sachs Group assumed coverage on United Therapeutics in a report on Thursday, September 24th. They set a “sell” rating and a $321.00 price objective on the stock. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Royal Bank Of Canada lowered their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $621.00.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A Delaware federal court ruled that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid, strengthening the competitive position of United Therapeutics’ Tyvaso franchise. United Therapeutics prevails in patent litigation
• Positive Sentiment: The decision could limit Yutrepia’s use in the PH-ILD market and may support United Therapeutics’ request for FDA action requiring labeling that excludes the disputed indication. Investors view the ruling as potentially extending Tyvaso’s market protection and supporting future cash flow. UTHR prevails in Yutrepia patent dispute
• Neutral Sentiment: The ruling may still face appeals, additional legal proceedings, or regulatory delays, so the timing and ultimate commercial benefit remain uncertain. Analyst opinions are mixed, with some bullish targets but at least one notably bearish view, creating potential volatility. Analysts have conflicting sentiments on healthcare companies
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.5 million on October 1, following another 9,500 shares sold over the prior two days. EVP Paul Mahon also sold 8,300 shares for approximately $4.7 million. The transactions may reflect scheduled selling, but the concentration of insider sales can weigh on sentiment after the stock’s sharp advance. United Therapeutics insider selling

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.